Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells

Patrick J. Hensley, Andreas Desiniotis, Chi Wang, Arnold Stromberg, Ching Shih Chen, Natasha Kyprianou

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Cancer cell resistance to anoikis driven by aberrant signaling sustained by the tumor microenvironment confers high invasive potential and therapeutic resistance. We recently generated a novel lead quinazoline-based Doxazosin® derivative, DZ-50, which impairs tumor growth and metastasis via anoikis. Genome-wide analysis in the human prostate cancer cell line DU-145 identified primary downregulated targets of DZ-50, including genes involved in focal adhesion integrity (fibronectin, integrin-α6 and talin), tight junction formation (claudin-11) as well as insulin growth factor binding protein 3 (IGFBP-3) and the angiogenesis modulator thrombospondin 1 (TSP-1). Confocal microscopy demonstrated structural disruption of both focal adhesions and tight junctions by the downregulation of these gene targets, resulting in decreased cell survival, migration and adhesion to extracellular matrix (ECM) components in two androgen-independent human prostate cancer cell lines, PC-3 and DU-145. Stabilization of cell-ECM interactions by overexpression of talin-1 and/or exposing cells to a fibronectin-rich environment mitigated the effect of DZ-50. Loss of expression of the intracellular focal adhesion signaling effectors talin-1 and integrin linked kinase (ILK) sensitized human prostate cancer to anoikis. Our findings suggest that DZ-50 exerts its antitumor effect by targeting the key functional intercellular interactions, focal adhesions and tight junctions, supporting the therapeutic significance of this agent for the treatment of advanced prostate cancer.

Original languageEnglish
Article numbere86238
JournalPLoS ONE
Volume9
Issue number1
DOIs
StatePublished - Jan 31 2014

Funding

FundersFunder number
National Center for Research Resources
National Institutes of Health (NIH)R01-GRANT00491815
National Center for Research ResourcesUL1RR033173

    ASJC Scopus subject areas

    • General Biochemistry, Genetics and Molecular Biology
    • General Agricultural and Biological Sciences
    • General

    Fingerprint

    Dive into the research topics of 'Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells'. Together they form a unique fingerprint.

    Cite this